These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 27983764)

  • 21. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
    Richardson PG; Blood E; Mitsiades CS; Jagannath S; Zeldenrust SR; Alsina M; Schlossman RL; Rajkumar SV; Desikan KR; Hideshima T; Munshi NC; Kelly-Colson K; Doss D; McKenney ML; Gorelik S; Warren D; Freeman A; Rich R; Wu A; Olesnyckyj M; Wride K; Dalton WS; Zeldis J; Knight R; Weller E; Anderson KC
    Blood; 2006 Nov; 108(10):3458-64. PubMed ID: 16840727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
    Jakubowiak AJ; Richardson PG; Zimmerman T; Alsina M; Kaufman JL; Kandarpa M; Kraftson S; Ross CW; Harvey C; Hideshima T; Sportelli P; Poradosu E; Gardner L; Giusti K; Anderson KC
    Br J Haematol; 2012 Aug; 158(4):472-80. PubMed ID: 22640031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial.
    Kumar S; Sharma A; Malik PS; Gogia A; Pathak N; Sahoo RK; Gupta R; Prasad CP; Kumar L
    Br J Haematol; 2022 Jul; 198(2):288-297. PubMed ID: 35499209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.
    Roussel M; Lauwers-Cances V; Robillard N; Hulin C; Leleu X; Benboubker L; Marit G; Moreau P; Pegourie B; Caillot D; Fruchart C; Stoppa AM; Gentil C; Wuilleme S; Huynh A; Hebraud B; Corre J; Chretien ML; Facon T; Avet-Loiseau H; Attal M
    J Clin Oncol; 2014 Sep; 32(25):2712-7. PubMed ID: 25024076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma.
    Dhakal B; D'Souza A; Hamadani M; Arce-Lara C; Schroeder K; Chhabra S; Shah NN; Gauger K; Keaton T; Pasquini M; Hari P
    Blood Cancer J; 2019 Jul; 9(8):56. PubMed ID: 31358733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma.
    Baz RC; Shain KH; Hussein MA; Lee JH; Sullivan DM; Oliver EF; Nardelli LA; Nodzon LA; Zhao X; Ochoa-Bayona JL; Nishihori T; Dalton WS; Alsina M
    Am J Hematol; 2014 Jan; 89(1):62-7. PubMed ID: 24030918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma.
    Tufail M; Siegel DS; McBride L; Bilotti E; Bello E; Anand P; Olivo K; Bendarz U; McNeill A; Vesole DH
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):186-90. PubMed ID: 22381702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM).
    Leleu X; Terpos E; Sanz RG; Cooney J; O'Gorman P; Minarik J; Greil R; Williams C; Gray D; Szabo Z
    Am J Hematol; 2016 Aug; 91(8):806-11. PubMed ID: 27169523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure.
    Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M
    Eur J Haematol; 2004 Aug; 73(2):98-103. PubMed ID: 15245508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.
    Schey S; Brown SR; Tillotson AL; Yong K; Williams C; Davies F; Morgan G; Cavenagh J; Cook G; Cook M; Orti G; Morris C; Sherratt D; Flanagan L; Gregory W; Cavet J;
    Br J Haematol; 2015 Aug; 170(3):336-48. PubMed ID: 25891006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
    Lu J; Lee JH; Huang SY; Qiu L; Lee JJ; Liu T; Yoon SS; Kim K; Shen ZX; Eom HS; Chen WM; Min CK; Kim HJ; Lee JO; Kwak JY; Yiu W; Chen G; Ervin-Haynes A; Hulin C; Facon T
    Br J Haematol; 2017 Mar; 176(5):743-749. PubMed ID: 28106903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience.
    Alegre A; Oriol-Rocafiguera A; Garcia-Larana J; Mateos MV; Sureda A; Martinez-Chamorro C; Cibeira MT; Aguado B; Knight R; Rosettani B
    Leuk Lymphoma; 2012 Sep; 53(9):1714-21. PubMed ID: 22292853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
    Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
    N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.
    Berenson JR; Yellin O; Kazamel T; Hilger JD; Chen CS; Cartmell A; Woliver T; Flam M; Bravin E; Nassir Y; Vescio R; Swift RA
    Leukemia; 2012 Jul; 26(7):1675-80. PubMed ID: 22354206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma.
    Chim CS; Kumar S; Wong VKC; Ngai C; Kwong YL
    Hematology; 2021 Dec; 26(1):652-655. PubMed ID: 34474661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Vesole DH; Bilotti E; Richter JR; McNeill A; McBride L; Raucci L; Anand P; Bednarz U; Ivanovski K; Smith J; Batra V; Aleman A; Sims T; Guerrero L; Mato A; Siegel DS
    Br J Haematol; 2015 Oct; 171(1):52-9. PubMed ID: 26018491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone.
    Sun HL; Atenafu EG; Yeboah E; Reece DE; Trudel S; Kukreti V; Masih-Khan E; Winter A; Chen C
    Leuk Lymphoma; 2015 Feb; 56(2):407-14. PubMed ID: 24738975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma.
    Zagouri F; Roussou M; Kastritis E; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Kanellias N; Kalapanida D; Christoulas D; Migkou M; Terpos E; Dimopoulos MA
    Leuk Lymphoma; 2016 Aug; 57(8):1776-80. PubMed ID: 26916452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.
    Lonial S; Vij R; Harousseau JL; Facon T; Moreau P; Mazumder A; Kaufman JL; Leleu X; Tsao LC; Westland C; Singhal AK; Jagannath S
    J Clin Oncol; 2012 Jun; 30(16):1953-9. PubMed ID: 22547589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.